Pharmaceutical News

RSS

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

An experimental single-stranded oligonucleotide-based drug, MGN1703, comprised only of natural DNA components, stimulates the human immune system to fight infections and attack cancer cells without causing the harmful side effects associated with similar compounds that also contain non-natural DNA components.

8 Apr 2015

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

The combination of two well-known drugs will have unprecedented effects on pain management, says new research from Queen's.

8 Apr 2015

Northwestern University researchers find safer way to improve surgery outcomes

A Northwestern University research team potentially has found a safer way to keep blood vessels healthy during and after surgery.

7 Apr 2015

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Mylan N.V. today announced the U.S. launch of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott's Generess Fe Tablets.

7 Apr 2015

Medinatura now offers Traumeel and Zeel injections for knee OA

MediNatura Incorporated, a Delaware Corporation headquartered in greater Philadelphia, announced today that the company has become the exclusive importer for the following injection solutions: Traumeel, Zeel, LymphomyosotX, Spascupreel, Neuralgo-Rheum and Engystol.

7 Apr 2015

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Today in JAMA Pediatrics, researchers from The Children's Hospital of Philadelphia's (CHOP) PolicyLab published the largest study to date documenting the significant risks to children's health associated with prescription antipsychotics, a powerful a class of medications used to treat mental and behavioral health disorders.

7 Apr 2015

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen today announced that the European Commission approved a new use of Vectibix (panitumumab) as first-line treatment in combination with FOLFIRI for the treatment of adult patients with wild-type (WT) RAS metastatic colorectal cancer (mCRC).

6 Apr 2015

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

The Journal of Drugs in Dermatology is pleased to publish findings on a new injectable drug currently under development by Kythera Biopharmaceuticals, Inc. (Westlake Village, CA) that may provide a non-surgical alternative for people with double chins.

6 Apr 2015

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Sanford-Burnham Medical Research Institute today announced that it has signed a licensing agreement to further develop a first-in-class small molecule with Daiichi Sankyo for the treatment of cardiovascular-metabolic disease.

6 Apr 2015

Nanomedicine strategy can help reduce heart attacks, strokes

A research team showed that a nanotherapeutic medicine can halt the growth of artery plaque cells resulting in the fast reduction of the inflammation that may cause a heart attack, according to a study led by researchers from Icahn School of Medicine at Mount Sinai and published April 3 in Science Advances.

6 Apr 2015

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Astellas Pharma Inc. and The University of Texas MD Anderson Cancer Center today announced the signing of an option agreement to research and develop a new treatment for patients with acute myeloid leukemia (AML).

6 Apr 2015

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg.

6 Apr 2015

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Depomed, Inc. today announced that it has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes: NUCYNTA ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment; NUCYNTA (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults; and NUCYNTA (tapentadol) oral solution, an approved oral form of tapentadol that has not been launched.

6 Apr 2015

Leukemia drug could prevent and control growth of colorectal tumours

Scientists from Nanyang Technological University (NTU Singapore) and Sweden's Karolinska Institutet, one of Europe's largest and most prestigious medical universities, have discovered that an existing chemotherapy drug used to treat leukaemia could prevent and control the growth of colorectal tumours.

3 Apr 2015

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Dr. Jonathan Goldman, CEO, Aptuit LLC, announced that Aptuit has increased its global capacity for Active Pharmaceutical Ingredient (API) Manufacture due to increased demand for API, and for its integrated and comprehensive candidate-to-IND development solution.

3 Apr 2015

Medication adherence interventions for heart failure patients

Unlike some conditions, heart failure must be managed by patients taking prescriptions for the rest of their lives. Individuals who do not take their heart medication as prescribed have increased risks of mortality and hospitalization and higher health care costs.

3 Apr 2015

AMRI plans to close its API manufacturing facility in Holywell, U.K.

AMRI announced today that it has decided to close its Holywell, U.K. facility following a consultation process with employee representatives.

3 Apr 2015

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

ImmunoClin Corporation, a healthcare company specialized in personalized medicine, announces that its wholly owned subsidiary, ImmunoClin Ltd., received a controlled drug license from the UK government to possess, supply and produce schedule 1 drugs in its UK laboratory.

2 Apr 2015

Omeros announces commercial availability of Omidria in U.S.

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, announced today the nationwide commercial availability of Omidria (phenylephrine and ketorolac injection) 1%/0.3%.

2 Apr 2015

Purdue researchers identify new class of chemical insecticides to control mosquitoes

Purdue researchers have identified a new class of chemical insecticides that could provide a safer, more selective means of controlling mosquitoes that transmit key infectious diseases such as dengue, yellow fever and elephantiasis.

2 Apr 2015

Pharmaceutical News

Experimental oligonucleotide-based drug stimulates human immune system to fight infections

Combining nortriptyline and morphine successfully relieves chronic neuropathic pain

Northwestern University researchers find safer way to improve surgery outcomes

Mylan announces the U.S. launch of first generic version of Generess Fe tablets

Medinatura now offers Traumeel and Zeel injections for knee OA

Antipsychotic drugs may elevate child's risk for weight gain, type II diabetes

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Journal of Drugs in Dermatology publishes findings on new injectable drug ATX-101

Sanford-Burnham, Daiichi Sankyo sign licensing agreement to expand development of small molecule

Nanomedicine strategy can help reduce heart attacks, strokes

Astellas Pharma, MD Anderson sign option agreement to research and develop new treatment for AML

Actavis seeks FDA marketing approval for Ambrisentan Tablets, 5 mg and 10 mg

Depomed acquires U.S. rights to NUCYNTA franchise from Janssen Pharmaceuticals

Leukemia drug could prevent and control growth of colorectal tumours

Aptuit increases API capacity to meet increased demand for integrated candidate-to-IND solutions

Medication adherence interventions for heart failure patients

AMRI plans to close its API manufacturing facility in Holywell, U.K.

ImmunoClin receives controlled drug license to supply, produce schedule 1 drugs in UK

Omeros announces commercial availability of Omidria in U.S.

Purdue researchers identify new class of chemical insecticides to control mosquitoes

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News